View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 11, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Larimar Therapeutics Reports First Quarter 2024 Operating and Financia...

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2 dose exploration study data demonstrated nomlabofusp was generally well-tolerated with dose-dependent increases in tissue frataxin levels, reinforcing therapeutic potentialBiologics License Application (“BLA”) submission targeted for 2H 2025; discussions initiated with Food and Drug Administration (“FDA”) on potential to pursue accelerated approval pathwaySuc...

 PRESS RELEASE

EMCORE Reports Fiscal 2024 Second Quarter Results

EMCORE Reports Fiscal 2024 Second Quarter Results BUDD LAKE, NJ, May 08, 2024 (GLOBE NEWSWIRE) -- EMCORE Corporation (Nasdaq: EMKR), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, today announced results for the fiscal 2024 second quarter (2Q24) ended March 31, 2024. Management will host a conference call to discuss 2Q24 financial and business results on May 8, 2024 at 5:00 p.m. Eastern Time (ET). “Lower-than-expected revenue in the March quarter was primarily due to product shipment delays and declining revenue from our B...

Hawthorn Bancshares Inc: 1 director

A director at Hawthorn Bancshares Inc bought 15,000 shares at 19.626USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

EMCORE Corporation to Host Fiscal 2024 Second Quarter Conference Call ...

EMCORE Corporation to Host Fiscal 2024 Second Quarter Conference Call on May 8, 2024 BUDD LAKE, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- EMCORE Corporation (Nasdaq: EMKR), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, will announce its fiscal 2024 second-quarter results for the period ended March 31, 2024, on Wednesday, May 8, 2024, after the market close. Conference Call and Webcast Information The Company will host a conference call to discuss the results at 2:00 p.m. PT (5:00 p.m. ET) on Wednesday, May 8, 2024. Presid...

 PRESS RELEASE

EMCORE Announces Sale of Chips Business and Wafer Fabrication Operatio...

EMCORE Announces Sale of Chips Business and Wafer Fabrication Operations for $2.92M and Certain Assumed Liabilities BUDD LAKE, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- EMCORE Corporation (Nasdaq: EMKR), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, announced today the consummation effective April 30, 2024 of a transaction for the sale of its Chips business and indium phosphide (InP) wafer fabrication operations for a total purchase price of $2.92 million, together with the assumption by the buyer, HieFo Corporation, of certain...

 PRESS RELEASE

Hawthorn Bancshares Announces Cash Dividend

Hawthorn Bancshares Announces Cash Dividend JEFFERSON CITY, Mo., April 24, 2024 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced today that its Board of Directors approved a quarterly cash dividend of $0.19 per common share, payable July 1, 2024 to shareholders of record at the close of business on June 15, 2024, which represents an increase of $0.02 per common share from the prior quarter's dividend. About Hawthorn Bancshares, Inc. Hawthorn Bancshares, Inc., a financial-bank holding company headquartered in Jefferson City, Missouri, is the parent company of Hawtho...

 PRESS RELEASE

Hawthorn Bancshares Reports First Quarter 2024 Results

Hawthorn Bancshares Reports First Quarter 2024 Results JEFFERSON CITY, Mo., April 24, 2024 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK), (the “Company”), the bank holding company for Hawthorn Bank, reported first quarter 2024 net income of $4.5 million and earnings per diluted share (“EPS”) of $0.63. First Quarter 2024 Results Net income of $4.5 million, or $0.63 per diluted share, an increase of 34.0% per diluted share from the first quarter 2023 (the "prior year quarter")Net interest margin, fully taxable equivalent ("FTE") of 3.39%Return on average assets and equity o...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: March 19, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operati...

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue frataxin levels observedInitiated discussions with the Food and Drug Administration (FDA) on the potential use of tissue frataxin levels as a novel surrogate endpoint to support a Biologics License Application (“BLA”) submission for accelerated approval targeted for 2H 2025In January 2024, initiated ope...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: March 14, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Larimar Therapeutics Announces the Dosing of the First Patient in Long...

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia Study will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin data and safety data from the OLE study are intended to help support a potential Biologics License Application (“BLA”) submission for accelerated approval targeted for H2 2025Initial data expected in Q4 2024 BALA CYNWYD, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, In...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 9, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch